<DOC>
	<DOC>NCT02418845</DOC>
	<brief_summary>The purpose of this clinical trial is to test the safety and efficacy of the oral investigational new drug, SYM-1219 for the treatment of bacterial vaginosis.</brief_summary>
	<brief_title>A Phase 3 Study of SYM-1219 Treatment of Women and Post-Menarchal Adolescent Girls With Bacterial Vaginosis</brief_title>
	<detailed_description />
	<mesh_term>Vaginal Diseases</mesh_term>
	<mesh_term>Vaginosis, Bacterial</mesh_term>
	<criteria>Are premenopausal adult females or post menarchal adolescent girls ≥12 years of age in good general health Have a clinical diagnosis of bacterial vaginosis, defined as having all of the following criteria: Offwhite (milky or gray), thin, homogeneous vaginal discharge Vaginal pH ≥ 4.7 Presence of Clue cells of ≥ 20% of the total epithelial cells on microscopic examination of the vaginal saline wet mount A positive 10% KOH Whiff test Have a Gram stain slide Nugent Score ≥ 4 at the Baseline Visit (Day 1) Are pregnant, lactating, or planning to become pregnant during the study Are menstruating or have vaginal bleeding at the Baseline Visit (Day 1) Are suspected clinically (or confirmed diagnostically) of having alternative causes of vaginal symptoms including candidiasis, Chlamydia trachomatis, Trichomonas vaginalis, Neisseria gonorrhoeae or Herpes simplex Have received antifungal or antimicrobial therapy (systemic or intravaginal) within 14 days prior to the Baseline Visit (Day 1)</criteria>
	<gender>Female</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>